LENZ Therapeutics, Inc.
LENZ · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.15 | -0.04 | -0.02 | -1.90 |
| FCF Yield | -9.74% | -59.81% | -76.79% | -12.02% |
| EV / EBITDA | -11.98 | -0.54 | -0.83 | -1.58 |
| Quality | ||||
| ROIC | -28.53% | -39.12% | -34.31% | -15.61% |
| Gross Margin | 0.00% | 0.00% | 44.36% | 0.00% |
| Cash Conversion Ratio | 1.19 | 0.86 | 0.87 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | – | – | – |
| Free Cash Flow Growth | 0.91% | 36.12% | -61.41% | -470.74% |
| Safety | ||||
| Net Debt / EBITDA | 0.38 | 0.28 | 0.43 | 5.38 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -26,789.74 | -37.91 | -98.88 | -228.75 |